We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

Sarah O’Keeffe recounts her fulfilling career path with Eli Lilly from employee to Senior Vice President, Product Research ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...

Released on Friday, February 7, the January jobs report showed resilience in the labor market with higher-than-expected wage ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

New DTC platforms like LillyDirect and PfizerForAll are triggering a paradigm shift in how pharma companies connect with patients.

We ran that screen on Feb. 15 last year, using data as of the market close the previous day. Nvidia's (NVDA) stock has returned 80% from Feb. 14, 2024, through Tuesday, while the S&P 500 SPX has ...

The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating.